The global metastatic castration-sensitive prostate cancer treatment market is witnessing significant expansion. This rise can be linked to factors such as an elevating population, rising prevalence of prostate cancer, and progresses in treatment choices. The market is further driven by greater awareness about the disease and its treatment options.